Patents Assigned to Aegis Therapeutics, LLC
  • Absorption enhancers for intranasal administration
    Patent number: 8927497
    Abstract: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: January 6, 2015
    Assignee: Aegis Therapeutics, LLC.
    Inventor: Edward T. Maggio
  • Intranasal administration of active agents to the central nervous system
    Patent number: 8883728
    Abstract: Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: November 11, 2014
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Stabilizing alkylglycoside compositions and methods thereof
    Patent number: 8846044
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: September 30, 2014
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Stabilizing alkylglycoside compositions and methods thereof
    Patent number: 8772231
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of insulin or an analog thereof.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: July 8, 2014
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Absorption Enhancers for Drug Administration
    Publication number: 20140128479
    Abstract: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicant: Aegis Therapeutics, LLC.
    Inventor: Edward T. Maggio
  • Compositions for drug administration
    Patent number: 8642564
    Abstract: A composition having at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms and wherein the therapeutic agent is an oligonucleotide.
    Type: Grant
    Filed: February 25, 2008
    Date of Patent: February 4, 2014
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Absorption enhancers for intranasal interferon administration
    Patent number: 8551468
    Abstract: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: October 8, 2013
    Assignee: Aegis Therapeutics LLC
    Inventor: Edward T. Maggio
  • Compositions for Drug Administration
    Publication number: 20130253009
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
    Type: Application
    Filed: May 13, 2013
    Publication date: September 26, 2013
    Applicant: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Multimodal particulate formulations
    Patent number: 8530463
    Abstract: Multimodal particulate formulations of medicaments and methods for their use, e.g. by nasal or pulmonary administration for the treatment of various medical conditions, are provided.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: September 10, 2013
    Assignees: Hale Biopharma Ventures LLC, Aegis Therapeutics, LLC
    Inventors: Steve Cartt, David Medeiros, Edward T. Maggio
  • Controlled release formulations
    Patent number: 8470370
    Abstract: The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: June 25, 2013
    Assignees: Aegis Therapeutics, LLC, The UAB Research Foundation
    Inventors: Edward T. Maggio, Elis Meezan, Dennis J. Pillion, Sarah L. Morgan, Joe Baggott
  • Compositions for drug administration
    Patent number: 8440631
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: May 14, 2013
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Controlled Release Formulations
    Publication number: 20130089595
    Abstract: The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.
    Type: Application
    Filed: November 28, 2012
    Publication date: April 11, 2013
    Applicants: THE UAB RESEARCH FOUNDATION, AEGIS THERAPEUTICS, LLC
    Inventors: Aegis Therapeutics, LLC, The UAB Research Foundation
  • ORALLY BIOAVAILABLE PEPTIDE DRUG COMPOSITIONS AND METHODS THEREOF
    Publication number: 20130034597
    Abstract: The present invention provides orally bioavailable peptide drug compositions including a cyclic peptide and an orally compatible absorption enhancer, as well as methods for providing increased oral bioavailability of peptide drugs.
    Type: Application
    Filed: February 3, 2012
    Publication date: February 7, 2013
    Applicant: AEGIS THERAPEUTICS LLC
    Inventor: Edward T. Maggio
  • Controlled release formulations
    Patent number: 8329220
    Abstract: The present invention provides stable, self-assembling, biocompatible and biodegradable hydrogel formulations, into which one or more compounds may be incorporated allowing for delayed release or controlled release of the incorporated compounds as the hydrogel is degraded in the body.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: December 11, 2012
    Assignees: Aegis Therapeutics, LLC, The UAB Research Foundation
    Inventors: Edward T. Maggio, Elias Meezan, Dennis J. Pillion, Sarah L. Morgan, Joe Baggott
  • Alkylglycoside compositions for drug administration
    Patent number: 8268791
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: September 18, 2012
    Assignee: Aegis Therapeutics, LLC.
    Inventor: Edward T. Maggio
  • Stabilizing alkylglycoside compositions and methods thereof
    Patent number: 8226949
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: July 24, 2012
    Assignee: Aegis Therapeutics LLC
    Inventor: Edward T. Maggio
  • Stabilizing alkylglycoside compositions and methods thereof
    Patent number: 8173594
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or analog thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: May 8, 2012
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • ALKYLSACCHARIDE COMPOSITIONS WITH NUTRACEUTICALS
    Publication number: 20120070487
    Abstract: The present invention provides nutraceutical compositions with enhanced oral bioavailability. The compositions of the present invention include one or more alkylsaccharides admixed with one or more nutraceutical.
    Type: Application
    Filed: March 23, 2011
    Publication date: March 22, 2012
    Applicant: AEGIS THERAPEUTICS LLC
    Inventor: Edward T. Maggio
  • Stabilizing alkylglycoside compositions and methods thereof
    Patent number: 8133863
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrir releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: March 13, 2012
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Stabilizing alkylglycoside compositions and methods thereof
    Patent number: 8084022
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example interferons, such as interferon-alpha, interferon-beta, interferon-gamma, and variants thereof.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: December 27, 2011
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio